Please login to the form below

Not currently logged in
Email:
Password:

cell cancer

This page shows the latest cell cancer news and features for those working in and with pharma, biotech and healthcare.

Vyriad inks immunotherapy alliance with Merck/Pfizer

Vyriad inks immunotherapy alliance with Merck/Pfizer

an inflammatory reaction in the tumours, while avelumab take the brake off a T-cell mediated immune response in a double-whammy against the cancer, according to Vyriad’s chief executive ... cell lung cancer and also had a knockback in third-line

Latest news

More from news
Approximately 1 fully matching, plus 659 partially matching documents found.

Latest Intelligence

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Meanwhile, the pharma industry is hitting new heights in drug innovation, including cures for diseases such as hepatitis C, haemophilia and huge progress in cancer and cell and gene therapy - but ... IQVIA’s Angela McFarlane, presenting her

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck’s success in oncology will likely continue, driven by Keytruda’s lead in the frontline non-small cell lung cancer setting, ”says Cai Xuan, senior analyst, oncology and haematology, GlobalData. ... It will also be interesting to see how gene

  • Digital disruption Digital disruption

    That cloud-based tool, called the BioModel Analyzer (BMA), brings alive the millions of potential changes in cell signalling that make cancer cells multiply uncontrollably. ... Next, they draw in the basic signalling pathways that can go wrong in cancer

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody therapeutics.

  • Deal Watch January 2017 Deal Watch January 2017

    Using a similar structure, Takeda also announced a collaboration with possible future acquisition of Maverick which focuses on next-generation T-cell cancer research. ... 160. Kite Pharma. Fosun Pharma. Formation of a JV. Autologous T-cell therapies in

More from intelligence
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... and renal cell carcinoma (kidney cancer).

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics